Abstract
Major bleeding is a common threat in patients requiring antiplatelet therapy. Timing and intensity with regard to resumption of antiplatelet therapy represent a major challenge in clinical practice. Knowledge of the patient's bleeding risk, defining transient/treatable and permanent/untreatable risk factors for bleeding, and weighing these against thrombotic risk are key to successful prevention of major adverse events. Shared decision-making involving various disciplines is essential to determine the optimal strategy. The present article addresses clinically relevant questions focusing on the most life-threatening or frequently occurring bleeding events, such as intracranial hemorrhage and gastrointestinal bleeding, and discusses the evidence for antiplatelet therapy resumption using individual risk assessment in high-risk cardiovascular disease patients.
Original language | English |
---|---|
Pages (from-to) | 135-149 |
Number of pages | 15 |
Journal | Thrombosis and Haemostasis |
Volume | 123 |
Issue number | 02 |
Early online date | 4 Jul 2022 |
DOIs | |
Publication status | Published - Feb 2023 |
Keywords
- ATRIAL-FIBRILLATION
- CARDIOVASCULAR EVENTS
- CEREBRAL AMYLOID ANGIOPATHY
- DRUG-ELUTING STENTS
- HELICOBACTER-PYLORI INFECTION
- LOW-DOSE ASPIRIN
- MYOCARDIAL-INFARCTION
- PERCUTANEOUS CORONARY INTERVENTION
- PRECISE-DAPT SCORE
- PROTON PUMP INHIBITORS
- antiplatelet therapy
- aspirin
- bleeding
- dual antiplatelet therapy
- gastrointestinal bleeding
- intracranial bleeding
- resumption of antiplatelet therapy